Diplomat Selected to Dispense KITABIS™ PAK for Cystic Fibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Diplomat Pharmacy (DPLO) Prices Larger 8.54M Common Follow-on at $29/Share
March 26, 2015 7:30 AM EDTDiplomat Pharmacy (NYSE: DPLO) announced the pricing of its follow-on public offering of 8,540,109 shares of common stock at a price to the public of $29.00 per share. Diplomat is selling 5,540,109 shares of common stock and certain shareholders of Diplomat are selling 3,000,000 shares of common stock.... More
Diplomat Pharmacy (DPLO) Selected for PARI's KITABIS PAK Limited-Distribution Panel
March 17, 2015 8:47 AM EDTDiplomat Pharmacy (NYSE: DPLO) announced its selection today to the limited-distribution panel for PARI's KITABIS PAK, recently approved by the U.S. Food and Drug Administration for patients with cystic fibrosis.
Cystic fibrosis is a life-threatening disease that affects nearly 30,000 American patients. The condition... More
